Effect of intensive therapy of multiple factors intervention on vascular complications in type 2 diabetes

Abstract

The effects of intensive versus regular therapy on incidence and progress of microalbuminuria in type 2 diabetes were compared. During a follow-up of 3 years, 96 cases of diabetes mellitus were randomized to intensive and regular therapy groups. HbA_1c goal was same in the two groups, but the goal of blood pressure (Bp) and lipid was more strict in the intensive therapy group than in the regular therapy group. There was statistically significant difference in the incidence and progression of vascular complications between the two groups. Logistic stepwise-regression analysis (odds ration, OR) showed that there was significant difference in the progression of nephropathy (OR 0.24, 95% CI 0.12–0.76), retinopathy (OR 0.38, 95% CI 0.16–0.88), peripheral neuropathy (OR 0.42, 95% CI 0.22–0.86) and autonomic neuropathy (OR 0.29, 95% CI 0.12–0.86) between the two groups (P<0.01). It was concluded that intensive blood glucose controlling could retard diabetic vascular complications. Intensive therapy of multiple factors interventions (controlling Bp, regulating blood lipid, improving microcirculation) could decrease various risk factors for diabetic vascular complications.

Keywords

type 2 diabetes / vascular complications / multiple factors intervention / intensive therapy

References

[1] ShichiriM, KishikawaH, OhkuboY, et al.. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 2000, 23(Suppl 2): B21-B21

[2] LevinS R, CoburnJ W, AbrairaC, et al.. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Diabetes Care, 2000, 23: 1478-1478

[3] EstacioR O, JeffersB W, GiffordN, et al.. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care, 2000, 23(Suppl2): B54-B54

[4] United Kingdom Prospective Study (UKPDS) Group. Intensive blood control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352(9131): 837-837

[5] TimothyC F. Evolution of the joint national committee reports, 1988–1997. Evolution of the science of treating hypertension. Arch Intern Med, 1997, 157(21): 2401-2401

[6] LamK S, ChengI K, JanusE D, et al.. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia, 1995, 38: 604-604